Folotyn for Non-Hodgkin's Lymphoma Baltimore MD

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Laurence Austin Doyle, MD
(410) 328-2567
22 S Greene St
Baltimore, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Md Sch Of Med, Baltimore Md 21201
Graduation Year: 1978

Data Provided by:
Karen M Ezrine, MD
(410) 966-1965
3801 Canterbury Rd Unit 917
Baltimore, MD
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Jefferson Med Coll-Thos Jefferson Univ, Philadelphia Pa 19107
Graduation Year: 1972

Data Provided by:
Michael C Garofalo
(410) 328-3037
22 S Greene St
Baltimore, MD
Specialty
Radiation Oncology

Data Provided by:
Chad Michael Deyoung, MD
(410) 328-6080
29 S Greene St
Baltimore, MD
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Wayne State Univ Sch Of Med, Detroit Mi 48201
Graduation Year: 1999

Data Provided by:
Edward Anthony Sausville
(410) 328-7394
22 S Greene St
Baltimore, MD
Specialty
Medical Oncology

Data Provided by:
Robert G Slawson
(410) 328-3037
22 S Greene St
Baltimore, MD
Specialty
Radiation Oncology

Data Provided by:
Panayotis Ledakis
(410) 783-5858
227 St Paul Place
Baltimore, MD
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Ivana Gojo
(410) 328-5793
22 S Greene St
Baltimore, MD
Specialty
Hematology / Oncology

Data Provided by:
Katherine Hanna Tkaczu, MS
(410) 328-2567
22 S Greene St # S9D12
Baltimore, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Kavita Boveja Kalra, MD
(410) 328-7157
22 S Greene St # S9D10
Baltimore, MD
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: St George'S Univ, Sch Of Med, St George'S, Grenada
Graduation Year: 1999

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com